| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Profit before tax | -32.0 | -3.1 |
| Net income | -32.0 | -3.1 |
| EPS (diluted, $ a share) | $-0.40 | $-2.36 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: DMRA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Damora Therapeutics, Inc.: key numbers
- Share price
- $22.56Close, Nov 17
- Market cap
- $1.4B
- Shares outstanding
- 61.9MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Damora Therapeutics, Inc.
All →Damora Therapeutics Director, President and CEO Jennifer Jarrett Buys $253K of Stock
Jennifer Jarrett, Director, President and CEO, bought 12,500 shares of Damora Therapeutics, Inc. at $20.23 a share, worth $253K in total on Sep 25, 2026. Shares held after the trade: 512,500 (+2.5%).
- Value
- $253K
- Shares
- 12,500
- Price
- $20.23
- Role
- Director, President and CEO
- Holding change
- +2.5%
- Trade date
- Sep 25, 2026